Mode
Text Size
Log in / Sign up
Phase 2 N=32 Single-blind Treatment

Efficacy and Safety of Bisacodyl and Lactulose as a Preparation for Colonoscopy

Colonoscopy Preparation

Enrolled (actual)
32
Serious AEs
0.0%
Results posted
Feb 2016
Primary outcome: Primary: Efficacy of Bisacodyl and Lactulose as a Preparation for Colonoscopy. — 5.7; 7.4; 7.8 units on a scale

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
90 grams of Crystalline Lactulose (Drug); 135 grams of Crystalline Lactulose (Drug); 180 grams of Crystalline Lactulose (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Cumberland Pharmaceuticals
Primary completion
Aug 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
Efficacy of Bisacodyl and Lactulose as a Preparation for Colonoscopy.
5.7; 7.4; 7.8
SECONDARY
Safety of Bisacodyl and Lactulose as a Bowel evacuant_AE Incidence
25; 33; 50
SECONDARY
Safety of Bisacodyl and Lactulose as a Bowel evacuant_AE Severity
0; 25; 50; 25; 8; 0
SECONDARY
Tolerability of and Preference for Bisacodyl and Lactulose as a Bowel Evacuant
65.4; 68.5; 71.3

Summary

The purpose of the study is to evaluate the efficacy and safety of bisacodyl combined with escalating doses of lactulose to be used as a preparation for colonoscopy.

Eligibility Criteria

Inclusion Criteria

  • Patients requiring bowel evacuation for colonoscopy.

Exclusion Criteria

  • Patients with galactosemia (galactose-sensitive diet).
  • Patients known to be hypersensitive to any of the components of lactulose for oral solution.
  • Patients with a known abnormality on screening or a vital sign assessments that, in the Investigator's judgment, may pose a significant risk including those pertaining to dehydration or electrolyte shifts.
  • Patients with a history of impaired renal function.
  • Patients with current or recent history of hypotension, as defined by the Investigator.
  • Patients with a history of long Q-T syndrome.
  • Patients with a history of a failed bowel preparation.
  • Patients with severe constipation, defined as those patients taking daily prescription or over-the-counter laxatives.
  • Patients with possible bowel obstruction, gastric retention, bowel perforation, toxic colitis, toxic megacolon, ileus or previous colonic surgery (except hemorrhoidectomy and polypectomy).
  • Patients on lactulose therapy or receiving any treatment for chronic constipation.
  • Be pregnant or nursing.
  • Patients expected to require electrocautery or argon plasma coagulation.
  • Patients less than 18 years of age.
  • Inability to understand the requirements of the study or be unwilling to provide written informed consent (as evidenced by signature on an informed consent document approved by an Institutional Review Board [IRB]) and agree to abide by the study restrictions.
  • Be otherwise unsuitable for the study, in the opinion of the Investigator.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02123017). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search